Credit Suisse’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $3.1M | Buy |
11,603
+1,075
| +10% | +$253K | ﹤0.01% | 1587 |
|
|
2023
Q4 | $2.44M | Sell |
10,528
-172
| -2% | -$30.1K | ﹤0.01% | 1769 |
|
|
2023
Q3 | $1.56M | Sell |
10,700
-3,349
| -24% | -$630K | ﹤0.01% | 1985 |
|
|
2023
Q2 | $3.25M | Buy |
14,049
+3,559
| +34% | +$964K | ﹤0.01% | 1617 |
|
|
2023
Q1 | $2.54M | Buy |
10,490
+484
| +5% | +$132K | ﹤0.01% | 1732 |
|
|
2022
Q4 | $2.9M | Sell |
10,006
-62
| -0.6% | -$6.06K | ﹤0.01% | 1660 |
|
|
2022
Q3 | $655K | Buy |
10,068
+1,595
| +19% | +$111K | ﹤0.01% | 2626 |
|
|
2022
Q2 | $606K | Buy |
8,473
+279
| +3% | +$20.5K | ﹤0.01% | 2721 |
|
|
2022
Q1 | $804K | Buy |
8,194
+1,541
| +23% | +$130K | ﹤0.01% | 2679 |
|
|
2021
Q4 | $564K | Sell |
6,653
-1,059
| -14% | -$87K | ﹤0.01% | 3732 |
|
|
2021
Q3 | $615K | Buy |
7,712
+1,546
| +25% | +$134K | ﹤0.01% | 3672 |
|
|
2021
Q2 | $601K | Sell |
6,166
-2,856
| -32% | -$338K | ﹤0.01% | 3727 |
|
|
2021
Q1 | $1.05M | Sell |
9,022
-5,970
| -40% | -$696K | ﹤0.01% | 3283 |
|
|
2020
Q4 | $1.67M | Buy |
14,992
+4,739
| +46% | +$579K | ﹤0.01% | 2959 |
|
|
2020
Q3 | $1.22M | Sell |
10,253
-12,043
| -54% | -$1.31M | ﹤0.01% | 2785 |
|
|
2020
Q2 | $2.52M | Buy |
22,296
+9,363
| +72% | +$921K | ﹤0.01% | 2198 |
|
|
2020
Q1 | $863K | Sell |
12,933
-8,865
| -41% | -$739K | ﹤0.01% | 2774 |
|
|
2019
Q4 | $1.99M | Buy |
21,798
+13,335
| +158% | +$1.29M | ﹤0.01% | 2602 |
|
|
2019
Q3 | $729K | Buy |
8,463
+1,907
| +29% | +$179K | ﹤0.01% | 3221 |
|
|
2019
Q2 | $687K | Sell |
6,556
-410
| -6% | -$43.9K | ﹤0.01% | 3207 |
|
|
2019
Q1 | $871K | Sell |
6,966
-123
| -2% | -$15.3K | ﹤0.01% | 2991 |
|
|
2018
Q4 | $799K | Buy |
7,089
+1,349
| +24% | +$209K | ﹤0.01% | 2958 |
|
|
2018
Q3 | $1.23M | Sell |
5,740
-3,048
| -35% | -$765K | ﹤0.01% | 2716 |
|
|
2018
Q2 | $2.46M | Buy |
8,788
+2,995
| +52% | +$526K | ﹤0.01% | 2285 |
|
|
2018
Q1 | $677K | Buy |
5,793
+757
| +15% | +$93.4K | ﹤0.01% | 3196 |
|
|
2017
Q4 | $462K | Buy |
+5,036
| New | +$288K | ﹤0.01% | 3473 |
|
|
2016
Q3 | – | Sell |
-7,601
| Closed | -$69K | – | 4191 |
|
|
2016
Q2 | $69K | Buy |
7,601
+7,007
| +1,180% | +$84.1K | ﹤0.01% | 4116 |
|
|
2016
Q1 | $5K | Sell |
594
-318
| -35% | -$2.66K | ﹤0.01% | 3946 |
|
|
2015
Q4 | $11K | Sell |
912
-5
| -0.5% | -$137 | ﹤0.01% | 4188 |
|
|
2015
Q3 | $56K | Sell |
917
-3,431
| -79% | -$248K | ﹤0.01% | 4166 |
|
|
2015
Q2 | $340K | Buy |
4,348
+2,448
| +129% | +$205K | ﹤0.01% | 3953 |
|
|
2015
Q1 | $129K | Sell |
1,900
-2,660
| -58% | -$228K | ﹤0.01% | 4184 |
|
|
2014
Q4 | $423K | Sell |
4,560
-1,223
| -21% | -$126K | ﹤0.01% | 3826 |
|
|
2014
Q3 | $608K | Sell |
5,783
-1,174
| -17% | -$163K | ﹤0.01% | 3487 |
|
|
2014
Q2 | $996K | Buy |
6,957
+914
| +15% | +$134K | ﹤0.01% | 3285 |
|
|
2014
Q1 | $912K | Buy |
6,043
+786
| +15% | +$155K | ﹤0.01% | 3208 |
|
|
2013
Q4 | $964K | Buy |
5,257
+1,401
| +36% | +$257K | ﹤0.01% | 3308 |
|
|
2013
Q3 | $851K | Sell |
3,856
-3,430
| -47% | -$730K | ﹤0.01% | 3085 |
|
|
2013
Q2 | $1.27M | Buy |
+7,286
| New | +$1.9M | ﹤0.01% | 2611 |
|
Other funds holding MDGL
BBA
ACA
PC
PA
Credit Suisse's MDGL Position: Q1 2024 in Review
Credit Suisse increased its Madrigal Pharmaceuticals (MDGL) stake by 10% in Q1 2024, buying an estimated $253K and bringing the position to 11,603 shares worth $3.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1587.
Credit Suisse first reported a position in MDGL in Q2 2013 and has held it in 39 quarters since. The position peaked at $3.25M in Q2 2023. 268 funds tracked by Wall St. Rank hold MDGL as of Q1 2024.
- Credit Suisse held 11,603 shares of Madrigal Pharmaceuticals worth $3.1M as of Q1 2024.
- Credit Suisse bought 1,075 Madrigal Pharmaceuticals shares in Q1 2024, an estimated $253K.
- Madrigal Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1587 holding.
- Credit Suisse first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 39 quarters since.
- Credit Suisse's Madrigal Pharmaceuticals position peaked at $3.25M in Q2 2023.
- 268 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.